Tirzepatide injection sites: areas, rotation and device instructions

At a glance

• The labels describe subcutaneous use in the abdomen, thigh or upper arm.
• Rotate sites and avoid skin that is bruised, tender, damaged or scarred.
• A pen, KwikPen and compounded vial need different instructions.

The question this guide answers

The Zepbound device and presentation determine the technique. Rotate the labeled subcutaneous areas; switching body areas is not an established way to target belly fat.

Sources: Wegovy prescribing informationZepbound prescribing informationFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

Choose an area you can use safely

The medicine goes into the tissue under the skin, not a muscle or vein. The abdomen and thigh can be easier to reach independently; upper-arm administration may require help. Use the device instructions to identify the acceptable area and any distance to keep from the navel.

An injection location should be practical, comfortable and easy to inspect. Reports that one area feels different are not proof that the drug produces more weight loss there.

Sources: Wegovy prescribing informationZepbound prescribing informationFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

Rotate within and between areas

Do not repeatedly inject into the exact same spot. Track the date and location so that irritation or a missed injection does not become a guessing exercise. If you also use insulin, discuss spacing and administration with your clinician.

Sources: Wegovy prescribing informationZepbound prescribing informationFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

Have the pharmacy demonstrate your device

Request a demonstration and written instructions before the first dose. With a compounded vial, the concentration, syringe markings and prescribed amount must agree. A unit is not a fixed amount of semaglutide or tirzepatide across pharmacies.

Persistent swelling, spreading redness, an allergic reaction or uncertainty about the amount injected warrants medical guidance. Do not repeat a dose because you are unsure whether it worked.

Sources: Wegovy prescribing informationZepbound prescribing informationFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

Sources and review boundaries

Source check dates are listed below. First-party pages support descriptions of a service’s public offer; medical references support the educational context. They do not establish an independent clinical audit of a provider. This is general education, not personal medical advice; no named licensed clinical reviewer has reviewed this article.

1. Wegovy prescribing informationMedical or regulatory source · Source reviewed · 2026-10-02
2. Zepbound prescribing informationMedical or regulatory source · Source reviewed · 2026-10-02
3. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss Medical or regulatory source · Source reviewed · 2026-10-05

Related Articles

• GLP-1 medicines before surgery: what to tell the anesthesia team
• What to do when a GLP-1 shipment arrives warm
• Alcohol on semaglutide: risks and questions for your prescriber
• Alcohol on tirzepatide: risks and questions for your prescriber
• Semaglutide compounding pharmacies: sourcing, rules and open questions
• Tirzepatide compounding pharmacies: sourcing, rules and open questions